4Carlin JB,Doyle LW.Statistics for clinicans.7:Sample size[J].J Paediatr Child Heath,2002,38(3):300-304.
5Siddoway LA,Thmpson KA,Mcalliser CB,et al.Polymorphis of propafenone metabolism and disposition in man:clinical and phannacokinetic consequences[J].Circulation,1987,75(4):785-791.
6Yunus,Warnica,Mithchell.Precoedial QTd interval disperion as prediator of ventrlcular fibrillation in acute myocardial infarction[J].PACE,1994,17(5):752-755.
8Epstein AE,Bigger JT,Wyse DS,et al.Events in the cardioc Arrhythmia Supperssion Trial(CAST):Mortality in the entrie population enrolled[J].J Am Coil Cardiol,1991,18(1):14-19.
9Ravid S,Pedrik PJ,Novrit B.Safety of long-term,propafenone therapy for cardiac arrhythmia:experience with 774 patients[J].J Electrophysiol,1987,1(1):580-590.
10Podrid PJ,Beau SL Antiarrhythmic drug therapy for congestive heart failure with focus on Moricizine[J].Am J Cardiol,1990,65(8):56D-64D.
